Category: Law

Directors Guild Denies Violating Obamacare

… medicine and avoided surgeries, but according to the lawsuit, he was told in October 2014 that the DGA Producer Health Plan wouldn’t pay for naturopathic care. He and Grossman claim that the refusal of coverage violates the Affordable Care Act’s …

Reshaping life in nursing homes

… in 2014 and in return, facilities must comply with government rules. The new regulations, proposed last year by Health and Human Services Secretary Sylvia Mathews Burwell, take effect in three phases. The first kicked in late last year. They allow …

Democrats prepare major effort to save Obamacare

… protect it by touting all of its benefits. “This is not just about the 20 million previously uninsured who now have health security,” House Minority Leader Nancy Pelosi, D-California, said during a call with reporters Monday. “But this is about the …

Nancy Pelosi urges voters to reconsider Affordable Care Act

Senior House Democrats are extolling the benefits of President Barack Obama’s health care law in hopes of derailing Republican plans to gut the statute. Speaking to reporters Monday, House Minority Leader Nancy Pelosi says the GOP will begin its “assault” on the law when the 115th Congress convenes Tuesday.

Democrats extol health care law in bid to derail GOP repeal

Senior House Democrats are extolling the benefits of President Barack Obama’s health care law in hopes of derailing Republican plans to gut the statute. Speaking to reporters Monday, House Minority Leader Nancy Pelosi says the GOP will begin its “assault” on the law when the 115th Congress convenes Tuesday.

Pelosi’s Obamacare plea: ‘Take a second look’

House Democrats who ushered President Barack Obama’s health care reforms into law say they failed to sell it from the start. On a call Monday with top Democrats, House Minority Leader Nancy Pelosi said one thing she would have done differently on health care reform from the start was “message it in a much stronger way.”

Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year

Despite a generally bleak year for Gilead, and for biotech stocks in general, shares of Exelixis, Inc. Can these biotechs continue climbing throughout the new year and beyond, or are they about to sputter and run out of fuel? Let’s look at what’s propelling them upward to see why they might be better picks than Gilead Sciences. A string of good news for Exelixis’ lead cancer drug made this one of the best-performing biotech stocks of 2016.

Darrell Issa Proposes ‘Tort Reform’ To Replace Obamacare

Rep. Darrell Issa asserted on Sunday that part of the solution for replacing President Barack Obama’s health care law is to give patients fewer rights when suing doctors for malpractice. During a panel discussion on CNN’s State of the Union , Delaware Democratic Representative-elect Lisa Blunt Rochester pointed out that many of her constituents relied on the Affordable Care Act.

Medicaid expansion, casinos among Hassan’s wins and losses

Democratic Gov. Maggie Hassan officially becomes a U.S. senator on Tuesday, ending four years of leading New Hampshire from her corner office. Her two terms in office were marked by accomplishments, including providing subsidized health care to 50,000 low-income people, and by failures, such as her unsuccessful drive to legalize a casino.

Judge blocks Obama’s transgender mandate

A Texas judge has temporarily blocked the Obama administration’s new requirements for transgender care, granting a preliminary injunction Saturday to several states and religious health organizations suing over the rules. The rule, which was slated to go into effect Jan. 1, says that doctors can’t refuse to provide medically necessary health services within their scope of practice because of a patient’s gender identity.

Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals

Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals In 2016, these two stocks have taken paths as varied as their approaches to drug development, and the past few months have been a wild ride.

Report cites gains from Ohio’s Medicaid expansion

With President-elect Donald Trump and congressional Republicans planning to repeal Obamacare, Gov. John Kasich’s administration released a report Friday saying that Ohio’s 2014 Medicaid expansion has improved the health and reduced financial hardships for hundreds of thousands of poor Ohioans.

New rules to limit Medi-Cal ‘death fees’

… estate recovery program collected close to $70 million, says Tony Cava, spokesman for the state Department of Health Care Services, which administers Medi-Cal. That’s up from roughly $53 million in 2011-2012. Sen. Ed Hernandez, D-West Covina, points …

Obama, Democrats to Consider Ways to Save Affordable Care Act

President Barack Obama will meet with Democrats in Congress on Wednesday to discuss ways to protect his signature health care law, which Republicans have threatened to repeal. The president and Democratic lawmakers hope to devise a strategy to delay the Republican-controlled House and Senate from repealing much of the Affordable Care Act without providing a replacement plan.

Exelixis Inc. (EXEL) Stake Raised by Swiss National Bank

Swiss National Bank increased its position in shares of Exelixis Inc. by 1.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 367,300 shares of the biotechnology company’s stock after buying an additional 5,600 shares during the period.

Alere -1.2% as it appeals revoked Medicaid billing for Arriva

Alere is down another 1.2% in after-hours trade following news that its Arriva Medical unit — the largest contract supplier for diabetes testing supplies under the Medicare National Mail Order Competitive Bid Program — has appealed a decision to revoke its Medicare billing privileges. Arrival appealed to an administrative law judge at the Centers for Medicare and Medicaid Services; it expects the appeal to be heard within 30 days and a decision within three months.

Synergy: A Buy, Just Not Right Now

Shares of Synergy Pharmaceuticals are trading about flat over the past year, although they are up over 50% since achieving a double bottom in the first half of the year. The company is an up and coming player in developing novel gastrointestinal therapies, with the majority of their efforts being focused on plecanatide.

Biotech Poised for Rebound

… election of Donald Trump has buoyed the prospects of financials, energy and industrials. After an initial surge, health-care and biotech have not benefited nearly as much as other industries but definitely not as badly as utilities or consumer …